KCT0002909招募中未知
Changes in 18F-NaF PET/CT and 18F-FDG PET/CT after 223Ra Dichloride Treatment in Patients with Breast Cancer with Osseous Metastases
Korea Cancer Center Hospital0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 80(Year)（—）
- 性别
- Female
入选标准
- •1. Histopathologically confirmed breast cancer patients with positive estrogen receptors, HER2 negative (ER + / HER2-)
- •2. Breast cancer patients with confirmed bone metastases
- •- who has radiologic evidence of at least two measurable bone metastases (radionuclide bone scan, CT scan or MRI) within 12 weeks of the clinical trial drug administration.
- •- There is no involvement in soft tissue metastasis.
- •3. Persons who are receiving at least 3 months of endocrine therapy or bisphosphonate therapy and are expected not to change their treatment plan during the course of the study.
- •4. Before enrolling clinical trials, listen to the test person in sufficient detail for the purpose of the examination, the contents of the test, the characteristics of the test drug, etc., and the patient or the subject signed by the guardian or legal representative
- •5. Patients aged 19 to 80 years
- •6. The Eastern Cooperative Oncology Group (ECOG) _ Performance scale =2
- •7. Those who meet the following conditions in the blood test
- •- absolute neutrophil count (ANC) = 1,500/µL
- •- Platelet count (PLT) = 100,000/µL
- •- hemoglobin = 10 g/dL (100g/L; 6.2 mmol /L)
排除标准
- •1. A person who is judged to be difficult to perform a clinical trial due to a serious medical condition
- •2. Visceral metastases as assessed
- •3. Those who are deemed to need chemotherapy within the next 6 months
- •4. Those who plan to change or plan to undergo new endocrine therapy or bisphosphonate treatment during the course of the study
- •5. Those who received chemotherapy, immunotherapy or external radiation therapy within 4 weeks of initiation of clinical studies
- •6. The person who is determined to have a mental disorder that is difficult to perform PET scan
- •7. Those participating in other clinical trials at screening, and those in clinical trials who may be involved in the acquisition of 18F-FDG or 18F-NaF PET images
- •8. Those who have participated in other clinical trials that may affect the acquisition of 18F-FDG or 18F-NaF PET images from the time of registration until the end of the study or that may affect the safety evaluation following intravenous injection of 223Ra.
- •9. Those who have the potential to influence the acquisition of 18F-FDG PET images due to unadjusted diabetes
- •10. If the pregnancy has been confirmed at the beginning of the clinical study, or if there is a possibility of pregnancy during the period of the clinical study
- •11. Who should breastfeed during the period of clinical research
- •12. Any other person who is deemed not to be eligible to participate in the trial
- •13. Vulnerable subjects (researchers or students who participated in the research, family members, researchers or students of researchers participating in research)
研究者
相似试验
招募中
不适用
Changes in 18F-NaF PET/CT and 18F-FDG PET/CT after 223Ra Dichloride Treatment in Patients With Locally Recurrent of Metastatic OsteosarcomaKCT0002905Korea Cancer Center Hospital20
招募中
不适用
Changes in 18F-NaF PET/CT and 18F-FDG PET/CT after 223Ra Dichloride Treatment in Patients With Castration-Resistant Prostate Cancer with Osseous MetastasesKCT0002899Korea Cancer Center Hospital20
已完成
不适用
The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomyBladder cancerJPRN-UMIN000043722Al Zahraa Hospital300
招募中
3 期
18F-fluciclovine PET/CT and 18F-DCFPyL PET/CT in patients with biochemical recurrence of disease after radical prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.malignancy of the prostate10036958Prostate cancerNL-OMON50844Vrije Universiteit Medisch Centrum50
进行中（未招募）
1 期
A prospective imaging study with 18F-fluciclovine PET/CT and 18F-DCFPyL in patients with biochemical reccurence of prostate cancer.Prostate cancerEUCTR2021-001123-40-NLAmsterdam UMC, VU University Medical Center50